Allopurinol Offers No Cardiovascular Benefit

Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients.
Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients.

Allopurinol therapy is not associated with beneficial cardiovascular outcomes in gout patients, according to a study.

The study included 4,966 patients with newly diagnosed gout: 2,483 on allopurinol and 2,483 not on the drug. Subjects were matched for age, gender, diabetes, hypertension, hyperlipidemia, and atrial fibrillation.

After a median follow-up of 5.2 years, the allopurinol group had a modest 20% increase in cardiovascular risk compared with the non-allopurinol group, Victor C. Kok, MD, of Kuang Tien General Hospital, Shalu, Taichung, Taiwan, and colleagues reported online in PLoS One (9:e99102). This increased to 25% after adjusting for chronic kidney disease, uremia, and gastric ulcers.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.